crisaborole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5201 906673-24-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • staquis
  • crisaborole
  • AN2728
  • eucrisa
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
  • Molecular weight: 251.05
  • Formula: C14H10BNO3
  • CLOGP: 2.63
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 62.48
  • ALOGS: -4.03
  • ROTB: 2

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 27, 2020 EMA Pfizer Europe MA EEIG
Dec. 14, 2016 FDA ANACOR PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pain 2118.81 71.76 330 2471 3468 50598855
Burning sensation 702.67 71.76 204 2597 45242 50557081
Application site erythema 258.49 71.76 58 2743 4480 50597843
Drug ineffective 146.55 71.76 200 2601 819133 49783190
Application site pruritus 134.59 71.76 33 2768 3726 50598597
Skin burning sensation 127.06 71.76 39 2762 10146 50592177
Drug effective for unapproved indication 127.05 71.76 28 2773 1981 50600342
Dermatitis atopic 115.89 71.76 29 2772 3557 50598766
Application site swelling 111.84 71.76 20 2781 478 50601845
Condition aggravated 94.59 71.76 98 2703 296960 50305363
Eyelid irritation 90.17 71.76 16 2785 365 50601958
Drug ineffective for unapproved indication 88.51 71.76 36 2765 21245 50581078
Eczema 86.26 71.76 36 2765 22666 50579657
Product use in unapproved indication 76.63 71.76 58 2743 115761 50486562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pain 1143.65 166.29 166 1014 1513 29571834
Burning sensation 400.46 166.29 98 1082 15840 29557507
Application site erythema 176.84 166.29 35 1145 2064 29571283
Drug ineffective 166.52 166.29 126 1054 363044 29210303

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site pain 2084.04 77.77 323 2687 3925 64491797
Burning sensation 611.10 77.77 180 2830 49484 64446238
Application site erythema 352.23 77.77 73 2937 4616 64491106
Drug ineffective 309.47 77.77 275 2735 839972 63655750
Application site pruritus 180.02 77.77 40 2970 3499 64492223
Condition aggravated 145.00 77.77 127 2883 372299 64123423
Dermatitis atopic 118.56 77.77 29 2981 3847 64491875
Drug ineffective for unapproved indication 111.26 77.77 45 2965 31088 64464634
Skin burning sensation 106.34 77.77 33 2977 10550 64485172
Application site swelling 97.25 77.77 18 2992 624 64495098
Eczema 96.11 77.77 40 2970 29680 64466042
Pruritus 94.95 77.77 93 2917 312307 64183415
Off label use 86.43 77.77 125 2885 632681 63863041
Erythema 85.08 77.77 70 2940 187000 64308722
Application site irritation 81.13 77.77 18 2992 1558 64494164

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AH06 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Agents for dermatitis, excluding corticosteroids
FDA MoA N0000182960 Phosphodiesterase 4 Inhibitors
FDA EPC N0000182961 Phosphodiesterase 4 Inhibitor
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:50748 antipsoriatic drug
CHEBI has role CHEBI:68844 phosphodiesterase IV inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.8 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL 8501712 Feb. 16, 2027 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL 9682092 Feb. 16, 2027 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL 8168614 Jan. 20, 2030 METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL June 14, 2022 PEDIATRIC EXCLUSIVITY
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL March 23, 2023 NEW PATIENT POPULATION
2% EUCRISA ANACOR PHARMS INC N207695 Dec. 14, 2016 RX OINTMENT TOPICAL Sept. 23, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Phosphodiesterase 4 Enzyme INHIBITOR IC50 6.31 SCIENTIFIC LITERATURE DRUG LABEL
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Enzyme IC50 5.21 CHEMBL
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Enzyme IC50 6.14 CHEMBL

External reference:

IDSource
Q2R47HGR7P UNII
C4301781 UMLSCUI
CHEBI:134677 CHEBI
CHEMBL484785 ChEMBL_ID
44591583 PUBCHEM_CID
DB05219 DRUGBANK_ID
D10873 KEGG_DRUG
9151 IUPHAR_LIGAND_ID
1865953 RXNORM
248463 MMSL
32196 MMSL
724007009 SNOMEDCT_US
763593001 SNOMEDCT_US
4036360 VANDF
017053 NDDF
C543085 MESH_SUPPLEMENTAL_RECORD_UI
10024 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Staquis HUMAN PRESCRIPTION DRUG LABEL 1 0009-2211 OINTMENT 20 mg TOPICAL EXPORT ONLY 1 sections
Eucrisa HUMAN PRESCRIPTION DRUG LABEL 1 55724-211 OINTMENT 20 mg TOPICAL NDA 27 sections